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Aims and Method.T oe v a l u a t et h ep r a c t i c a lu t i l i t yo fo ﬀ-licence prescribing and clinical outcomes of treatment with atypical
antipsychoticMelperone.Method:Prospectivedatacollectiononpatient’sclinicalcharacteristicsandoutcomes.Results.17patients
with a diagnosis of refractory schizophrenia were identiﬁed as suitable for oﬀ-license prescribing of Melperone and commenced
treatment (13 were previously treated with Clozapine). Seven of those currently remain on Melperone (41%), and for six patents,
the BPRS symptom scores reduced signiﬁcantly over time (24–61%) additionally patients displayed improvements of their quality
of life. Six patients were discontinued due to noncompliance and/or side eﬀects. Melperone was ineﬀective in the other four
patients. Clinical Implications. The example of a small group of patients responding well to a comparably safe and inexpensive
atypical antipsychotic with favourable side eﬀect proﬁle should encourage clinicians to use this tool as third-line treatment and to
conduct more systematic clinical research.
1.Introduction
Themanagementofchronic,treatment-resistantschizophre-
nia remains a major challenge for mental health services.
The incidence of treatment-resistant schizophrenia has been
reported to be between 20% [1] and about one-third of the
patients not adequately responding to treatment [2]. With
the introduction of the so-called new-generation atypical
antipsychotics,greatertreatmentchoiceforpatientssuﬀering
from schizophrenia became available. This is particularly
helpful with regard to unpleasant extrapyramidal side eﬀects
of the older-generation antipsychotics. Negative symptoms
do not respond well to any antipsychotic medication, the
most recent UK NICE guidelines for schizophrenia update
states that there is currently no conclusive evidence for any
antipsychotic having superior eﬃcacy for persistent negative
symptoms [3].
The only substance with an established evidence base for
the treatment of refractory schizophrenia so far is Clozapine.
In the key study by Kane et al. [4], 30% of treatment
resistant patients responded to Clozapine compared to 4%
with Chlorpromazine. The superior eﬃcacy of Clozapine
has also been conﬁrmed in a meta-analysis of randomised
trials [5]. However, there is a group of patients that do not
respondtoClozapine,donotcomplywithblood-monitoring
requirements, or develop serious side eﬀects, which restrict
its use. For patients with treatment-resistant, chronic schiz-
ophrenia and those who suﬀer predominantly from negative
symptoms, the choice of available treatments (antipsychotics
andother)remains thereforeratherlimited. InEurope,other
antipsychotics with favourable side eﬀect proﬁles, some of
them considered to be classiﬁed as atypicals, are being used
whichareunlicensedintheUK(e.g.,Perazine,Pipamperone,
and Melperone). This group of antipsychotics has not2 The Scientiﬁc World Journal
been suﬃciently evaluated but may be worth exploring as
additionaltreatmentoptionsforpatientsintheUKandother
countries.
Melperoneisonesuchantipsychotic.Despitethefactthat
it is a butyrophenone derivative, it is said to have atypical
properties. It was ﬁrst used clinically in the 1960s. According
to the company’s [6] product information, in vitro studies
show that the aﬃnity of Melperone for the D2 receptor is
weaker than for haloperidol and that its antiserotonergic
activity (5-HT2 antagonist) is strong. Its anticholinergic and
antihistaminergic properties are low. A receptor occupancy
study found striatal D2 occupancies of around 70% in
patients treated with 250–300mg Melperone. This level of
occupancy is suﬃcient for clinical eﬀects but too low to raise
prolactin levels [7, 8]. It is therefore well tolerated with a
low risk of extrapyramidal side eﬀects or tardive dyskinesia
at clinically eﬀective doses. Due to its low incidence of
extrapyramidal symptoms, Melperone was used in the
treatment of iatrogenic psychosis in Parkinson’s disease [9].
Melperone is regarded to be a safe antipsychotic drug, and it
has been widely used in old-age psychiatry on the continent
due to its favourable proﬁle with low antimuscarinergic
a c t i v i t y ,a n dar e c e n ts t u d yf o u n dt h a tM e l p e r o n et r e a t m e n t
did not result in signiﬁcant weight gain [10]. There is only
one documented case of a fatal intoxication with Melperone
[11], the authors describe extremely high concentrations of
Melperone in the toxicological analysis and diazepam, and
nordazepam and carbamazepine were also detected.
According to its favourable clinical proﬁle, there has been
renewed interest in Melperone following studies suggesting
it can be eﬀective in neuroleptic-resistant schizophrenia
patients [12, 13]. In September 2005, East London NHS
Foundation Trust Medicines Committee approved the use of
Melperone for patients with treatment-resistant schizophre-
nia who have not responded to, or who are intolerant to
Clozapine.
2. Aim
It is to summarise clinical outcomes for every patient com-
menced on Melperone in the East London NHS Foundation
Trust since approval of its use by the Trust’s Medicines
Committee. Outcomes will include objective measurement
ofsymptomseverityandreasonsforstoppingtreatmentwith
Melperone. Reasons why Clozapine was unsuitable will also
be considered.
3. Method
The proposal for the prospective study, auditing outcomes
(eﬃcacy and safety) following introduction of the new pre-
scribing policy, was submitted to the Trust Audit and Ethics
Committee and subsequently approved. Written informed
consent was obtained from all participating patients. Clinical
notes were searched for the following data.
(1) Baseline and subsequent brief psychiatric rating
scale/BPRS scores [14]. These should have been
documented, as per the guidelines for the use of
Melperone (Table 1).
(2) Reasons for stopping Clozapine.
(3) Maximum dose of Melperone reached.
(4) Reason(s) for stopping Melperone.
(5) Any additional antipsychotic(s) in use whilst taking
Melperone.
Consultant psychiatrists were asked to provide state-
ments regarding clinical observations of change following
treatment with Melperone.
4. Results
17 patients (6 females and 11 males, diﬀerent ethnicity,
and mean age 39.3 years/sd 10.5, mean number of previous
hospitalisations 3.7/sd 2.0, mean duration of illness 13.6
years/sd 7.4) have been started on Melperone since 2005.
All included patients had a diagnosis of refractory (treat-
ment resistant) schizophrenia with ongoing both positive
a n dn e g a t i v es y m p t o m sd e s p i t ee x p o s u r et od i ﬀerent ﬁrst-
and second-generation antipsychotics. Of these patients, 7
currently remain on Melperone (41%) with a mean daily
dose of 340 mg (range 150–600mg/SD 112).
Demographic and clinical data for these patients is
summarised in Table 2.
We excluded three cases from the analysis for the follow-
ing reasons: two patients had no BPRS scores measured at
all, despite the requirements of the operational policy, and
the other two patients had a very low baseline BPRS (<30),
questioning the necessity for antipsychotic medication and
the criteria for refractory (treatment resistant) schizophre-
nia; all these four patients did not take Melperone for longer
than 2–4 weeks.
4.1. Reasons Why Clozapine Treatment Ended. 13 of the
17 patients had been prescribed Clozapine previously.
One patient had not been prescribed Clozapine previously
due to physical health limitations (severe metabolic syn-
drome/insuﬃciently controlled diabetes), one due to severe
obesity and the other two patients refused to comply with
necessary blood monitoring.
Of those 13 patients prescribed Clozapine, it was
necessary to end treatment for the following reasons: 3
developed neutropenia, 5 did not respond to treatment, 2
developed myocardiopathy, 1 developed paralytic ileus and
severe hypotension, and 2 patients developed severe weight
gain/obesity.
4.2. Reasons Why Melperone Treatment Was Not Commenced
or Ended. Those 10 patients (59%) who did not start or
continue treatment with Melperone did so for the following
reasons: six patients were non- or insuﬃciently compliant
with the treatment from the beginning. Reason for noncom-
pliance was not given for three of these patients. Headache
was cited as the cause for noncompliance in one patient, one
patient complained about stomach upset, and one patient
said he/she preferred depot injections to taking tablets.The Scientiﬁc World Journal 3
Table 1: Guidelines and requirements for the use of Melperone as deﬁned within ELFT medicines committee policy.
Melperone should be prescribed by a consultant psychiatrist.
The patient’s consent for use of an unlicensed drug must be sought and clearly documented in their medical notes.
The drug is considered for those with treatment-resistant schizophrenia who have not responded to, or cannot tolerate Clozapine.
Start at 25mg nocte and increase according to tolerability. In nonrefractory illness, 100–300mg/day may be eﬀective. Higher doses
in refractory illness.
Full blood count, ECG, and blood pressure prior to commencement.
Melperone should not be used in conjunction with another antipsychotic.
Melperone initiation form must be completed to allow monitoring and audit of patients.
Baseline and subsequent BPRS to allow formal assessments of mental state.
Prescribing continued by secondary care services.
Table 2: Those 7 patients who are currently continuing with Melperone.
Age Sex Ethnicity Duration illness
(years)/prev. hosp.
Current
dose
Baseline
BPRS
Followup BPRS-1
(3–6 months since
baseline test)
Followup BPRS-2
(12–24 months
since baseline test)
% change between
baseline and
BPRS-2
54 M White Cauc. 22/2 450mg 46 39 35 23.9%
35 F Asian 18/3 600mg 58 59 35 32.8%
31 M Asian 8/4 300mg 92 63 44 52.2%
32 M Afro-Carib. 14/4 600mg 66 72 72 −9.1%
34 M Black African 5/10 500mg 67 26 26 61.1%
24 M Asian 10/5 500mg 98 45 45 54.1%
36 F Afro-Carib. 7/2 450mg 54 28 28 48.2%
It was reported that Melperone was ineﬀective in the
other4patientswhosetreatmentwithMelperoneceased,two
of those patients were treated for less than 4 weeks and with
a maximum dose of 300mg; Table 3 summarises their scores.
Testing the diﬀerence between the BPRS total scores at
baseline with those after treatment with Melperone (N =
7; nonparametric data analysis due to small sample size)
the following signiﬁcant changes were found (Wilcoxon’s
matched-pairs test): (1) from baseline to 3–6 months
treatment: z =− 2.0, P = .043; (2) from baseline to 12–24
months treatment: z =− 2.2, P = .028.
Comments from consultant psychiatrists were recorded
forfourdiﬀerentpatients:(1)(quotingthepatient’saccount)
“My head is clearer. I can think more easily”; (2) (quoting a
carer’s account) “Despite continuing symptoms, the Melper-
one has made a dramatic diﬀerence to my wife’s quality of
life” and (quoting the care-coordinator’s account) “Regard-
less of previous medications, she had been withdrawn, only
poorlyattendingtoherpersonalhygiene...whichnowmeans
she can function to a degree and take care of herself and
her children with some support”; (3) “Excellent response
and went into remission” and “Everyone, even his family
said he was a new person and all the staﬀ on the ward were
delighted...before he was bouncing back and forth from
PICU and hospital for preceding three years”; (4) “Initially
he made favourable response with remission of psychotic
symptoms apart from transient ﬂeeting paranoid ideas such
that we were able to discharge him into the community.”
5. Discussion
Since Melperone was introduced as an oﬀ-licence prescribed
substance into the portfolio of antipsychotics available to
patients under the care of East London NHS Foundation
Trust (ELFT), only a relatively small number of patients
received this treatment over a period of ﬁve years. It is
important to mention that most patients were started on
Melperone by psychiatrists, who previously gained clinical
experiences prescribing Melperone in other European coun-
tries, where it has been available as a licensed antipsychotic
for long time. Only two UK trained psychiatrists included
Melperone into their portfolio of prescribing. It appears
that despite the fact of a widely acknowledged problem
with treatment-resistant schizophrenia and even though a
relevant percentage of patients cannot be commenced on or
continue treatment with Clozapine, the alternative of oﬀ-
licence prescribing is not considered suitable by most clini-
cians. One may speculate that this is due to systemic factors
such as risk averse culture in the NHS or concerns regarding
the logistics of prescribing, dispensing, and monitoring the
drug, but it could also be a result of a therapeutic nihilism
and lack of information gathering and circulating.
Most clinical trials evaluating the eﬃcacy of antipsy-
chotic medication deﬁne a response as a 20% reduction in
BPRS total score. This patient group has had an exhaustible
array of treatment options prior to Melperone. We have
seen a >20% reduction in six patients, some of them4 The Scientiﬁc World Journal
Table 3: Those 4 patients who stopped Melperone as it is considered “ineﬀective.”
Age Sex Race Duration illness/number of
previous hospitalisations
Duration of
treatment
Max. dose
reached Baseline BPRS Followup BPRS (time
since baseline test)
51 M Asian 20/3 13 months 400mg 62 63 (6 months)
35 M Black African 15/4 4 months 600mg 48 54 (7 weeks)
51 M White Cauc. 25/5 <1 month 200mg Not assessed Not assessed
49 F Asian 10/3 <1 month 300mg 78 75 (3 weeks)
displaying a very signiﬁcant clinical response, characterised
as a “remission” by their clinical teams for two patients.
Amongst those four patients not responding to treatment,
two were not treated over a suﬃcient period of time and
without increasing the dose to the maximum level. From
a clinical perspective, any success in terms of symptom
reduction is remarkable in a group of patients with treat-
ment refractory chronic schizophrenia. Following failure of
Clozapine exposure, nearly all of the patients in this sample
had hardly any pharmaceutical alternative for treatment left.
When considering outcome, it is important not to focus on
objective measures of psychopathological symptom reduc-
tion alone. There has been a clear subjective improvement
in all but one of the patients currently taking Melperone.
Future work should aim to address such changes in social
functioning and subjective quality of life in the context of
systematic assessments, using a range of established and
validated outcome measures.
Despite the fact that some patients reported mild side
eﬀects (mainly tiredness, dizziness, and blurred vision),
Melperone was well tolerated in this sample with no
occurrence of extrapyramidal symptoms despite relatively
high dosages administered. Although doses of 100–300mg
ad a ya r ec o n s i d e r e de ﬀective, doses of up to 600mg a day are
used in Scandinavia, where necessary. A study evaluating the
eﬃcacyoftwodiﬀerentdosagesofMelperone(100or400mg
daily) in a sample of 34 acutely hospitalised patients found
that both dosages resulted in “ameliorating psychopathology
and improving overall psychiatric status” [15].
The observed ﬁndings can only be discussed with
caution; there are relevant methodological limitations. Our
sample size of seventeen is small, and given the naturalistic
design, the BPRS scores were obtained by doctors currently
involved in the patient’s care. They were therefore not blind
to previous scores. We continue to collect data. It is however
clearly encouraging that a relevant proportion of the patients
treated with Melperone in this trust have had good clinical
outcomes. It is also useful to know that subjective mea-
sures (including carer views) could reveal further beneﬁts.
Considering the clinical and research implications of this
study, it appears that systematic research regarding eﬃcacy
and eﬀectiveness, ideally more randomized controlled trials,
is needed. However, Melperone is an “oﬀ-patent” drug
and with no potential for proﬁt; hence, clinical trials con-
ducted by the pharmaceutical industry and/or applications
for licensing from pharmaceutical companies will not be
forthcoming. Therefore, independent research trials should
be conducted by academic institutions with the support
of government research grants. In the interest of those
patients who do not respond to available treatments and
who therefore continue to suﬀer from refractory symptoms,
other Mental Health trusts in the UK should be encouraged
to introduce oﬀ-license prescribing of Melperone and other
antipsychotics with established clinical track record in other
countries. Given the experiences so far in this Trust, those
initiatives must be accompanied by systematic promoting
strategies in order to provide clinicians proactively with
necessary information. At the moment, the best possible care
for UK patients remains compromised as some treatment
options continue to fall by the wayside.
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